By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharma To Present At The 11th Biennial Ovarian Cancer Research Symposium 8/11/2016 11:29:49 AM
DelMar Pharma Announces Presentation At The European Association Of Neuro-Oncology (EANO) Annual Meeting In October 2016 7/21/2016 7:53:53 AM
DelMar Pharma To Ring The Nasdaq Stock Market Opening Bell On July 14 7/13/2016 8:21:07 AM
DelMar Pharma Announces Approval For Listing On NASDAQ 7/11/2016 7:21:25 AM
ASCO2016: DelMar Pharma Presents Phase I/II GBM Clinical Trial Data And Outlines Future Clinical Development Plans At ASCO 2016 Annual Meeting 6/6/2016 11:33:31 AM
DelMar Pharma Announces Successful Completion Of End-Of-Phase 2 Meeting With FDA On VAL-083 For The Treatment Of Refractory Glioblastoma Multiforme 5/25/2016 6:30:59 AM
DelMar Pharma Announces Reverse Stock Split In Preparation For Proposed Senior Exchange Uplisting 5/19/2016 8:50:04 AM
DelMar Pharma Announces Third Quarter Fiscal Year 2016 Financial Results And Corporate Update 5/13/2016 7:48:30 AM
DelMar Pharma Announces $5.6 Million Private Placement Of Preferred Shares 5/5/2016 6:28:29 AM
DelMar Pharma Release: FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer 4/21/2016 6:22:28 AM